David Fenton

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Andrea Bezjak, Dongsheng Tu, Lesley Seymour et al. · Journal of Clinical Oncology · 2006 · 294 citations · Full text

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood Goss, Andrew Arnold, Frances A. Shepherd et al. · Journal of Clinical Oncology · 2009 · 243 citations

Advanced Nsclc, Medicine, Phase Iii +12

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Scott A. Laurie, Benjamin Solomon, Lesley Seymour et al. · European Journal of Cancer · 2013 · 108 citations

Daily Oral Cediranib, Oncology, Metronomic Therapy +8

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

Michael P. Chu, Sunita Ghosh, Carole Chambers et al. · Clinical Lung Cancer · 2014 · 101 citations

Decreased Erlotinib Efficacy, Non–small-cell Lung Cancer, Oncology +7